MET Amplification clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Sorry, not currently recruiting here
To assess: - efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors…
at UCLA UCSF
Our lead scientists for MET Amplification research studies include Rahul Aggarwal Timothy Cloughesy.
Last updated: